FMP
Cassava Sciences, Inc.
SAVA
NASDAQ
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
2.33 USD
-0.0089 (-0.382%)
Historical Prices
From:
To:
We are unable to load the chart at this time.
About
ceo
Mr. Richard Jon Barry
sector
Healthcare
industry
Biotechnology
exchange
NASDAQ
Description
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.
CIK
0001069530
ISIN
US14817C1071
CUSIP
14817C107
Address
7801 North Capital of Texas Hi...
Phone
512 501 2444
Country
US
Employee
29
IPO Date
Jul 14, 2000
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
SAVA Financial Summary
CIK
0001069530
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
14817C107
ISIN
US14817C1071
Country
US
Price
2.33
Beta
-0.58
Volume Avg.
5.27M
Market Cap
112.15M
Shares
-
52-Week
2.23-42.2
DCF
2.89
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-1.69
P/B
-
Website
https://www.cassavasciences.com
Upgrades and Downgrades
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest SAVA News
It looks like there's no news available.
